Alex is one of the world’s leading experts at the intersection of health and technology. For the last 15 years he has lead the digital transformation of healthcare, both from within the industry at Johnson & Johnson and servicing the industry by founding and leading multiple award-winning agencies. Most recently he co-founded Foundry3 which houses the world's first digital health innovation Lab focussed on the pharmaceutical industry, the ‘Innovation Foundry’. Alex pioneered the application and integration of new philosophies and technologies within pharma, launching the first digital only marketing campaign supporting a pharmaceutical brand, he was the first to utilise social media and he commissioned and designed mobile health applications before the advent of the app store. This led to numerous digital marketing and communications awards, the inaugural recipient of the Global Social Media Pioneer award in Philadelphia in 2010 followed by the James E Burke Marketing Award for Uncommon Courage in 2011, the first pharma professional recipient. He has won over 30 PM Digital awards and the prestigious AXA PPP Global Health Technology Award 2017 with his work displayed in the Design Museum in London. Alex has been the brain child of ground breaking digital health solutions in respiratory disease, Pulmonary Arterial Hypertension, transplantation, opioid addiction, MS, diabetes and psoriasis among others. He is also an invited member of the Wharton Global Advisory Board on the Future of Advertising and a Fellow of the Chartered Institute of Marketing (FCIM).
The term ‘digital’ in 2018 is a dangerous one. We all live in a complex mixed reality where the confines of digital and non-digital channels are blurred. The focus is rightly on integration with and augmentation of the human experience. That being said, when we look at health, people turn to digital channels first when seeking help and when looking for on going support, digital and especially mobile, are the future of interventional relationships between healthcare providers, pharmaceutical companies and patients. When designing patient support programmes with a digital element these are the 5 key foundations you need to bear in mind:
My vision of a digital health revolution is in four parts, those being:
There can be no better insight into Pharma’s digital ambition than building a digital agency from scratch with pharmaceutical companies as the core client base. I have been working in pharma my whole career (now some 19 years) and feel very fortunate to have been around at a time of unprecedented change as technology has fundamentally impacted all aspects of the pharmaceutical business; from drug discovery and clinical trial development, through to the very nature of the product as health technology builds an evidence base and the focus moves from illness to wellness.
Improving people’s health and supporting improved clinical outcomes for patients is predominantly about behavioural change. Certainly digital health interventions are predicated on the idea that we can modify behaviour, whether this is adherence to medication or changes in lifestyle. Unfortunately this is not easy to achieve, human beings are complex and when it comes to health this complexity is magnified.
The term innovation belongs to that congregation of clichés that can be lazily used to evoke a sense of modernity and progression, often within industries or professions better known for conservatism and resistance to change.